Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19
Preemptive Use of Convalescent Plasma for High-risk Patients With SARS-CoV-2 Infection: Phase III-IV Non-controlled Non-randomised Swiss Multicentric Trial
Sponsor: Hôpital Fribourgeois
Listed as NCT04836260, this PHASE3 trial focuses on Covid19 and Immuno-Deficiency and remains ongoing. Sponsored by Hôpital Fribourgeois, it has been updated 4 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
May 2023 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
May 2021 — May 2023 [monthly]
Recruiting PHASE3
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hôpital Fribourgeois
- Ospedale Regionale di Lugano
- University Hospital, Basel, Switzerland
- University Hospital, Geneva
For direct contact, visit the study record on ClinicalTrials.gov .